229 related articles for article (PubMed ID: 2461688)
1. Distinguishing features of idiopathic flushing and carcinoid syndrome.
Aldrich LB; Moattari AR; Vinik AI
Arch Intern Med; 1988 Dec; 148(12):2614-8. PubMed ID: 2461688
[TBL] [Abstract][Full Text] [Related]
2. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
[TBL] [Abstract][Full Text] [Related]
3. [Pronounced flush symptoms in carcinoid syndrome without liver metastases].
Roth J; Raschka C; Hammar CH
Leber Magen Darm; 1994 Nov; 24(6):259-61. PubMed ID: 7531269
[TBL] [Abstract][Full Text] [Related]
4. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
[TBL] [Abstract][Full Text] [Related]
5. Pathophysiological causes and clinical significance of flushing.
Ray D; Williams G
Br J Hosp Med; 1993 Nov 17-Dec 14; 50(10):594-8. PubMed ID: 8293240
[TBL] [Abstract][Full Text] [Related]
6. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome.
Oberg K; Norheim I; Theodorsson E; Ahlman H; Lundqvist G; Wide L
J Clin Endocrinol Metab; 1989 Apr; 68(4):796-800. PubMed ID: 2466045
[TBL] [Abstract][Full Text] [Related]
7. Carcinoid syndrome. Medical management.
Clarke B; Hodgson HJ
Br J Hosp Med; 1986 Mar; 35(3):146-8, 150, 152. PubMed ID: 3742126
[TBL] [Abstract][Full Text] [Related]
8. [A prolonged-action somatostatin analog and carcinoid syndrome].
Chayvialle JA
Bull Acad Natl Med; 1989 May; 173(5):643-50; discussion 650-1. PubMed ID: 2478266
[TBL] [Abstract][Full Text] [Related]
9. Flush symptoms caused by a mesenteric carcinoid without liver metastases.
Sonnet S; Wiesner W
JBR-BTR; 2002; 85(5):254-6. PubMed ID: 12463502
[TBL] [Abstract][Full Text] [Related]
10. Biochemical assessment of niacin deficiency among carcinoid cancer patients.
Shah GM; Shah RG; Veillette H; Kirkland JB; Pasieka JL; Warner RR
Am J Gastroenterol; 2005 Oct; 100(10):2307-14. PubMed ID: 16181385
[TBL] [Abstract][Full Text] [Related]
11. Tachykinins in carcinoid tumors: their use as a tumor marker and possible role in the carcinoid flush.
Norheim I; Theodorsson-Norheim E; Brodin E; Oberg K
J Clin Endocrinol Metab; 1986 Sep; 63(3):605-12. PubMed ID: 2426299
[TBL] [Abstract][Full Text] [Related]
12. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.
Ruszniewski P; Ish-Shalom S; Wymenga M; O'Toole D; Arnold R; Tomassetti P; Bax N; Caplin M; Eriksson B; Glaser B; Ducreux M; Lombard-Bohas C; de Herder WW; Delle Fave G; Reed N; Seitz JF; Van Cutsem E; Grossman A; Rougier P; Schmidt W; Wiedenmann B
Neuroendocrinology; 2004; 80(4):244-51. PubMed ID: 15627802
[TBL] [Abstract][Full Text] [Related]
13. Flushing in the carcinoid syndrome and plasma kallikrein.
Lucas KJ; Feldman JM
Cancer; 1986 Nov; 58(10):2290-3. PubMed ID: 2428458
[TBL] [Abstract][Full Text] [Related]
14. Octreotide treatment of carcinoid hypertensive crisis.
Warner RR; Mani S; Profeta J; Grunstein E
Mt Sinai J Med; 1994 Sep; 61(4):349-55. PubMed ID: 7969229
[TBL] [Abstract][Full Text] [Related]
15. Primary carcinoid tumor of the bilateral testis associated with carcinoid syndrome.
Son HY; Ra SW; Jeong JO; Koh EH; Lee HI; Koh JM; Kim WB; Park JY; Shong YK; Lee KU; Kim GS; Kim MS
Int J Urol; 2004 Nov; 11(11):1041-3. PubMed ID: 15509216
[TBL] [Abstract][Full Text] [Related]
16. The carcinoid syndrome.
Maton PN
JAMA; 1988 Sep; 260(11):1602-5. PubMed ID: 2457717
[No Abstract] [Full Text] [Related]
17. Serotonin, catecholamines, and spontaneous midgut carcinoid flush: plasma studies from flushing and nonflushing sites.
Matuchansky C; Launay JM
Gastroenterology; 1995 Mar; 108(3):743-51. PubMed ID: 7533112
[TBL] [Abstract][Full Text] [Related]
18. [A favorable response to the somatostatin analog SMS 201-995 in a patient with the carcinoid syndrome].
Del Val A; Ponce J; Talens A; MartÃ-Bonmati L; Garrigues V; Berenguer J
Rev Esp Enferm Dig; 1991 Mar; 79(3):215-7. PubMed ID: 2043408
[TBL] [Abstract][Full Text] [Related]
19. Ophthalmic manifestations of the carcinoid flush.
Wong VG; Melmon KL
N Engl J Med; 1967 Aug; 277(8):406-9. PubMed ID: 4378294
[No Abstract] [Full Text] [Related]
20. Treatment of malignant carcinoid syndrome with a long-acting somatostatin analogue.
Altman AR; Tschen JA; Rice L
Arch Dermatol; 1989 Mar; 125(3):394-6. PubMed ID: 2923448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]